IP Library Granted Patent US 12,435,328
Granted Patent B2
US 12,435,328 · App. 16/955,525 · Granted Oct 7, 2025

Therapeutic enzyme fusion protein having a novel structure and use thereof

Inventors: Eui Joon Jung (Hwaseong-si, KR); Jin Young Kim (Hwaseong-si, KR); In Young Choi (Hwaseong-si, KR); Sung Youb Jung (Hwaseong-si, KR)
Assignee: HANMI PHARM. CO., LTD.
C12N9/96C12N9/2465C12N9/2471A61K38/00C07K2319/30C12N15/62C12Y302/01022C12Y302/01023
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,435,328
App. No.
16/955,525
Granted
Oct 7, 2025
Kind
B2
Abstract

A fusion protein of a dimeric therapeutic enzyme and an immunoglobulin Fc region, a preparation method thereof, and a composition containing the fusion protein are disclosed.

Claims (15)

1. An enzyme fusion protein of the following Formula 1:

wherein X and X′ are the same each other and each independently an enzyme and the enzyme forms a dimer through a non-covalent bond;

L and L′ are the same or different from each other, and are a peptide linker consisting of 10 to 50 amino acid residues;

F is an immunoglobulin Fc region obtained from immunoglobulin G4 (IgG4) and the immunoglobulin Fc region is in a monomer form;

| is a covalent bond; and

: is a non-covalent bond,

wherein the enzyme is selected from the group consisting of beta-glucosidase, alpha-galactosidase, beta-galactosidase, iduronidase, iduronate-2-sulfatase, galactose-6-sulfatase, acid alpha-glucosidase, acid ceramidase, acid sphingomyelinase, galactocerebrosidase, arylsulfatase A, B, beta-hexosaminidase A, B, heparin N-sulfatase, alpha-D-mannosidase, beta-glucuronidase, N-acetylgalactosamine-6 sulfatase, lysosomal acid lipase, alpha-N-acetyl-glucosaminidase, glucocerebrosidase, butyrylcholinesterase, chitinase, glutamate decarboxylase, imiglucerase, lipase, uricase, platelet-activating factor acetylhydrolase, neutral endopeptidase, and myeloperoxidase,

wherein the immunoglobulin Fc region comprises the amino acid sequence of SEQ ID NO: 8, wherein serine at position 2 is substituted with proline; or asparagine at position 71 is substituted with glutamine; or serine at position 2 is substituted with proline and asparagine at position 71 is substituted with glutamine.

2. The enzyme fusion protein of claim 1 , wherein the enzyme X and X′ form a dimer in anti-parallel configuration with each other.

3. The enzyme fusion protein of claim 1 , wherein the enzyme fusion protein has increased stability and reduced binding affinity for lysosome receptors, compared to an enzyme to which an immunoglobulin Fc region is not fused.

4. The enzyme fusion protein of claim 1 , wherein the enzyme is alpha-galactosidase A or beta-galactosidase.

5. The enzyme fusion protein of claim 1 , wherein no chain exchange occurs in the immunoglobulin Fc region.

6. The enzyme fusion protein of claim 1 , wherein the immunoglobulin Fc region is aglycosylated.

7. The enzyme fusion protein of claim 1 , wherein the enzyme comprises the amino acid sequence of SEQ ID NO: 6.

8. The enzyme fusion protein of claim 1 , wherein the enzyme fusion protein comprises the amino acid sequence of SEQ ID NO: 13.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2020
From: JUNG, EUI JOON; KIM, JIN YOUNG; CHOI, IN YOUNG; JUNG, SUNG YOUB
To: HANMI PHARM. CO., LTD.
Reel/Frame 054020/0807 →
Priority Claims (1)
KR 10-2017-0178378 · Dec 22, 2017 · national
Continuity (1)
Related Publication 20210009984A1 · Jan 14, 2021
References Cited (29)
US 20050281805A1 · Lebowitz et al. · 2005 [cited by applicant]
US 20080300188A1 · Yang et al. · 2008 [cited by applicant]
US 20200157172A1 · Heo · 2020 [cited by examiner]
EP 3650539A2 · 2020 [cited by applicant]
JP 2009521912A · 2009 [cited by applicant]
JP 2016526909A · 2016 [cited by applicant]
KR 100254759B1 · 2000 [cited by applicant]
KR 20020073127A · 2002 [cited by applicant]
KR 1020170091056A · 2017 [cited by applicant]
WO 9315210A1 · 1993 [cited by applicant]
WO 9632478A1 · 1996 [cited by applicant]
WO 9734631A1 · 1997 [cited by applicant]
WO 2006108586A2 · 2006 [cited by applicant]
WO 2015009052A1 · 2015 [cited by applicant]
WO 2017062619A2 · 2017 [cited by applicant]
WO 2017100467A2 · 2017 [cited by applicant]
Davos et al., (Proteins: Structure, Function and Genetics, 2000, vol. 41: 98-107. [cited by examiner]
Kwiatkowski et al., Biochemistry 38:11643-11650, 1999. [cited by examiner]
Wristlock et al., Quarterly Reviews of Biophysics 2003, vol. 36 (3): 307-340. [cited by examiner]
Kisselev L., Structure, 2002, vol. 10: 8-9. [cited by examiner]
Pilar Lloris-Garcerá et al., “Antiparallel Dimers of the Small Multidrug Resistance Protein EmrE Are More Stable Than Parallel Dimers”, The Journal of Biological Chemistry, Jul. 27, 2012, vol. 287, No. 31, pp. 26052-260… [cited by applicant]
[cited by applicant]
Michael Beck, “New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy”, Hum Genet, 2007, pp. 1-22, vol. 121. [cited by applicant]
Frances M. Platt et al., “Lysosomal storage disorders: The cellular impact of lysosomal dysfunction”, J. Cell Biol., pp. 723-734, vol. 199 No. 5. [cited by applicant]
Marijn Van Der Neut Kolfschoten et al., “Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange”, Science, Sep. 14, 2007, pp. 1554-1557, vol. 317. [cited by applicant]
International Search Report of PCT/KR2018/016487 dated Apr. 2, 2019 [PCT/ISA/210]. [cited by applicant]
Scott C. Garman, “Structure-function relationships in α-galactosidase A”, Acta Paediatr., 2007, vol. 96, No. 455 (30 pages total). [cited by applicant]
Decision on Registration dated Sep. 15, 2023 in Korean App. No. 10-2018-0167795. [cited by applicant]
JH Choi, et al., NCBI, Genbank, Accession No. NP_000160, “alpha-galactosidase A precursor [ [cited by applicant]